Skip to main content
. 2001 Jun 19;98(13):7443–7448. doi: 10.1073/pnas.131200498

Figure 3.

Figure 3

(a) Inhibition of C127 tumor growth by neutralizing mAb to HGF/SF. C-127 tumor cells were injected s.c. into athymic nude mice in PBS on day 0. Anti-HGF/SF mAbs A-1, -5, and -7 or mAb 7-2, -3, and -4 were administered either s.c. intratumor or i.p. every day for 20 days. One group of animals did not receive Ab. The values are an average of the size of five tumors in mm3. (b) Inhibition of U-118 glioblastoma tumor growth by neutralizing mAb to HGF/SF. U-118 human glioblastoma tumor cells were injected s.c. into athymic nude mice. On day 1, anti-HGF/SF mAbs A-1, -5, and -7 or mAbs 7-2 and -3 were administered either s.c. intratumor or i.p. twice a week for 10 weeks. One group of animals did not receive Ab. The values are an average size of six to seven tumors in mm3. (c) Tumor regression experiment using U-118 GBM cells. GBM cells were s.c. injected to athymic nude mice. After 30 days, animals were divided to five groups with average tumor size about 100 mm3. mAbs A-1, -5, and -7 or 7-2 and -3 were administered either s.c. intratumor or i.p. every 2 days until 10 weeks. One group of mice did not receive Ab. The values are an average size of eight to nine tumors in mm3.